Amphastar Pharmaceuticals, Inc.(AMPH)Earnings, Financials & Key Ratios

AMPH•NASDAQ

$23.90

$1.06B mkt cap·11.8× P/E·Price updated May 6, 2026

SectorHealthcare IndustrySpecialty & Generic Pharma Sub-IndustryComplex generics and injectables

AboutAmphastar Pharmaceuticals, Inc., a bio-pharmaceutical company, develops, manufactures, markets, and sells generic and proprietary injectable, inhalation, and intranasal products in the United States, China, and France. The company operates through two segments, Finished Pharmaceutical Products and API. It offers Primatene Mist, an over-the-counter epinephrine inhalation product for the temporary relief of mild symptoms of intermittent asthma; Enoxaparin, a low molecular weight heparin to prevent and treat deep vein thrombosis; Naloxone for opioid overdose; Glucagon for injection emergency kit; and Cortrosyn, a lyophilized powder for use as a diagnostic agent in the screening of patients with adrenocortical insufficiency. The company also provides Amphadase, a bovine-sourced hyaluronidase injection to absorb and disperse other injected drugs; Epinephrine injection for the emergency treatment of allergic reactions; lidocaine jelly, an anesthetic product for urological procedures; lidocaine topical solution for various procedures; phytonadione injection, a vitamin K1 injection for newborn babies; emergency syringe products for emergency use in hospital settings; morphine injection for use with patient controlled analgesia pumps; and lorazepam injection for surgery and medical procedures. In addition, it offers neostigmine methylsulfate injection to treat myasthenia gravis and to reverse the effects of muscle relaxants; and Isoproterenol hydrochloride injection for mild or transient episodes of heart block. Further, the company distributes recombinant human insulin active pharmaceutical ingredients (API) and porcine insulin API. It serves hospitals, care facilities, alternate care sites, clinics, and doctors' offices. The company was founded in 1996 and is headquartered in Rancho Cucamonga, California.Show more

Revenue$720M-1.7%
EBITDA$149M-43.2%
Net Income$98M-38.5%
EPS (Diluted)2.03-33.7%
Gross Margin49.46%-3.2%
EBITDA Margin20.71%-42.3%
Operating Margin19.5%-30.5%
Net Margin13.63%-37.5%
ROE12.9%-44.5%
ROIC8.4%-35.9%
Debt/Equity0.83-6.4%
Interest Coverage5.85-19.3%

Technical→

AMPH Key Insights

Amphastar Pharmaceuticals, Inc. (AMPH) fundamental analysis — strengths, weaknesses & financial health based on data analysis

✓Strengths

✓Strong 5Y profit CAGR of 133.8%
✓FCF machine: 16.8% free cash flow margin
✓High quality earnings: Operating CF exceeds net income
✓Strong 5Y sales CAGR of 15.5%
✓Good 3Y average ROE of 19.9%
✓Share count reduced 7.4% through buybacks

✗Weaknesses

No significant weaknesses identified

* These insights are generated automatically based on available financial data. Please conduct your own research before making investment decisions.

AMPH Price & Volume

Amphastar Pharmaceuticals, Inc. (AMPH) stock price & volume — 10-year historical chart

Loading chart...

AMPH Growth Metrics

Amphastar Pharmaceuticals, Inc. (AMPH) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR

Revenue CAGR

10 Years11.09%

5 Years15.53%

3 Years12.99%

TTM-1.33%

Profit CAGR

10 Years-

5 Years133.84%

3 Years2.39%

TTM-38.51%

EPS CAGR

10 Years-

5 Years134.54%

3 Years5.27%

TTM-33.66%

Return on Capital

10 Years8.02%

5 Years15.19%

3 Years15.13%

Last Year9.77%

AMPH Recent Earnings

Amphastar Pharmaceuticals, Inc. (AMPH) EPS & revenue vs analyst estimates — last 4 quarters

Full history →

●Beat EPS 8/12 qtrs (67%)●Beat Revenue 6/12 qtrs (50%)

Q1 2026Latest

Feb 26, 2026

EPS

$0.73

Est $0.90

-19.2%

Revenue

$183M

Est $189M

-3.0%

Q4 2025

Nov 6, 2025

EPS

$0.93

Est $0.77

+20.8%

Revenue

$192M

Est $190M

+0.7%

Q3 2025

Aug 7, 2025

EPS

$0.85

Est $0.71

+19.7%

Revenue

$174M

Est $177M

-1.5%

Q2 2025

May 7, 2025

EPS

$0.74

Est $0.66

+12.1%

Revenue

$171M

Est $173M

-1.5%

Quarter	Date	EPS (Act vs Est)	Revenue (Act vs Est)
Q1 2026Latest	Feb 26, 2026	$0.73vs $0.90-19.2%	$183Mvs $189M-3.0%
Q4 2025	Nov 6, 2025	$0.93vs $0.77+20.8%	$192Mvs $190M+0.7%
Q3 2025	Aug 7, 2025	$0.85vs $0.71+19.7%	$174Mvs $177M-1.5%
Q2 2025	May 7, 2025	$0.74vs $0.66+12.1%	$171Mvs $173M-1.5%

Based on last 12 quarters of dataView full earnings history →

Company	Market Cap	Stock Price	P/E Ratio (TTM)	Revenue Growth 1Y	Net Margin	Return on Equity (ROE)	Debt / Equity
LNTHLantheus Holdings, Inc.Direct Competitor	5.61B	86.15	25.26	0.5%	15.15%	20.58%	0.00
PCRXPacira BioSciences, Inc.Direct Competitor	931.85M	23.69	148.06	3.63%	1.27%	1.31%	0.66
PRGOPerrigo Company plcDirect Competitor	1.69B	12.26	-1.19	-2.75%	-43.5%	-50.65%	1.35
AKROAkero Therapeutics, Inc.Direct Competitor	4.5B	54.65	-14.57			-30.58%	0.05
SUPNSupernus Pharmaceuticals, Inc.Direct Competitor	2.96B	51.45	-75.66	8.63%	-3.74%	-2.73%	0.04
AKBAAkebia Therapeutics, Inc.Product Competitor	392.83M	1.48	-74	47.46%	-2.26%	-16.39%
MNKDMannKind CorporationProduct Competitor	1.1B	3.56	178	22.23%	-6.63%
NKTRNektar TherapeuticsProduct Competitor	1.67B	85.09	-8.75	-43.89%	-192.87%	-356.81%	0.95

Compare AMPH vs Peers

Amphastar Pharmaceuticals, Inc. (AMPH) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.

Closest Rival

vs LNTH

Most directly comparable listed peer for AMPH.

Scale Benchmark

vs MCK

Larger-name benchmark to compare AMPH against a more recognizable public peer.

Peer Set

Compare Top 5

vs LNTH, PCRX, PRGO, AKRO

AMPH Income Statement

Amphastar Pharmaceuticals, Inc. (AMPH) annual income statement — 10-year revenue, gross profit & net income history

10Y historyFree accessUpdated daily

Line item	Dec'17	Dec'18	Dec'19	Dec'20	Dec'21	Dec'22	Dec'23	Dec'24	Dec'25
Sales/Revenue	240.18M	294.67M	322.36M	349.85M	437.77M	498.99M	644.39M	731.97M	719.89M
Revenue Growth %	-5.87%	22.69%	9.4%	8.53%	25.13%	13.98%	29.14%	13.59%	-1.65%
Cost of Goods Sold	149.38M	187.68M	190.43M	206.51M	238.03M	250.13M	293.27M	358.11M	363.83M
COGS % of Revenue	62.2%	63.69%	59.08%	59.03%	54.37%	50.13%	45.51%	48.92%	50.54%
Gross Profit	90.8M▲ 0%	106.98M▲ 17.8%	131.92M▲ 23.3%	143.34M▲ 8.7%	199.74M▲ 39.3%	248.86M▲ 24.6%	351.12M▲ 41.1%	373.86M▲ 6.5%	356.06M▼ 4.8%
Gross Margin %	37.8%	36.31%	40.92%	40.97%	45.63%	49.87%	54.49%	51.08%	49.46%
Gross Profit Growth %	-12.86%	17.83%	23.31%	8.65%	39.35%	24.59%	41.09%	6.47%	-4.76%
Operating Expenses	94.33M	115.61M	131.96M	132.39M	129.85M	141.36M	154.13M	168.44M	215.65M
OpEx % of Revenue	39.28%	39.23%	40.94%	37.84%	29.66%	28.33%	23.92%	23.01%	29.96%
Selling, General & Admin	50.92M	58.04M	63.11M	65.16M	68.92M	66.59M	80.39M	94.52M	129.81M
SG&A % of Revenue	21.2%	19.7%	19.58%	18.62%	15.74%	13.35%	12.48%	12.91%	18.03%
Research & Development	43.41M	57.56M	68.85M	67.23M	60.93M	74.77M	73.74M	73.91M	85.84M
R&D % of Revenue	18.08%	19.54%	21.36%	19.22%	13.92%	14.98%	11.44%	10.1%	11.92%
Other Operating Expenses	0	0	0	0	0	0	0	0	0
Operating Income	-895K▲ 0%	-8.62M▼ 863.5%	-39K▲ 99.5%	10.95M▲ 28187.2%	69.89M▲ 538.0%	107.5M▲ 53.8%	196.99M▲ 83.2%	205.42M▲ 4.3%	140.4M▼ 31.7%
Operating Margin %	-0.37%	-2.93%	-0.01%	3.13%	15.96%	21.54%	30.57%	28.06%	19.5%
Operating Income Growth %	-105.7%	-863.46%	99.55%	28187.18%	538%	53.82%	83.25%	4.28%	-31.65%
EBITDA	14.91M	7.89M	21.08M	36.13M	96.42M	135.77M	238.76M	262.62M	149.1M
EBITDA Margin %	6.21%	2.68%	6.54%	10.33%	22.03%	27.21%	37.05%	35.88%	20.71%
EBITDA Growth %	-50.7%	-47.08%	167.1%	71.4%	166.84%	40.81%	75.86%	9.99%	-43.22%
D&A (Non-Cash Add-back)	15.81M	16.52M	21.12M	25.18M	26.53M	28.27M	41.78M	57.2M	0
EBIT	2.08M	-9.68M	60.35M	5.01M	85.02M	117.89M	198.52M	220.11M	149.1M
Net Interest Income	-401K	213K	878K	268K	-284K	-525K	-21.7M	-19.73M	-16.8M
Interest Income	425K	456K	997K	642K	601K	1.32M	5.46M	10.61M	8.68M
Interest Expense	826K	243K	119K	374K	885K	1.85M	27.16M	30.34M	25.48M
Other Income/Expense	2.52M	-1.3M	60.27M	-6.32M	14.04M	7.37M	-27.61M	-16.23M	-16.78M
Pretax Income	1.62M▲ 0%	-9.93M▼ 711.6%	60.23M▲ 706.8%	4.64M▼ 92.3%	83.93M▲ 1710.0%	114.86M▲ 36.9%	169.38M▲ 47.5%	189.19M▲ 11.7%	123.62M▼ 34.7%
Pretax Margin %	0.68%	-3.37%	18.68%	1.33%	19.17%	23.02%	26.28%	25.85%	17.17%
Income Tax	-2.88M	-3.27M	13.72M	3.54M	20.63M	23.48M	31.83M	29.67M	25.53M
Effective Tax Rate %	-177.76%	32.9%	22.79%	76.34%	24.58%	20.44%	18.79%	15.68%	20.65%
Net Income	4.51M▲ 0%	-5.74M▼ 227.3%	48.94M▲ 952.9%	1.4M▼ 97.1%	62.12M▲ 4327.4%	91.39M▲ 47.1%	137.54M▲ 50.5%	159.52M▲ 16.0%	98.09M▼ 38.5%
Net Margin %	1.88%	-1.95%	15.18%	0.4%	14.19%	18.31%	21.34%	21.79%	13.63%
Net Income Growth %	-57.2%	-227.28%	952.89%	-97.13%	4327.37%	47.12%	50.51%	15.98%	-38.51%
Net Income (Continuing)	3.65M	-6.66M	46.51M	1.1M	63.3M	91.39M	137.54M	159.52M	98.09M
Discontinued Operations	0	0	0	0	0	0	0	0	0
Minority Interest	0	31.92M	46.16M	46.42M	0	0	0	0	0
EPS (Diluted)	0.09▲ 0%	-0.12▼ 233.3%	0.98▲ 916.7%	0.03▼ 97.1%	1.25▲ 4270.6%	1.74▲ 39.2%	2.60▲ 49.4%	3.06▲ 17.7%	2.03▼ 33.7%
EPS Growth %	-59.09%	-233.33%	916.67%	-97.08%	4270.63%	39.2%	49.43%	17.69%	-33.66%
EPS (Basic)	0.10	-0.12	1.04	0.03	1.30	1.88	2.85	3.29	2.10
Diluted Shares Outstanding	48.37M	46.4M	49.91M	49.12M	49.78M	52.43M	53M	52.06M	48.22M
Basic Shares Outstanding	46.11M	46.4M	46.98M	47.04M	47.78M	48.55M	48.27M	48.43M	46.74M
Dividend Payout Ratio	-	-	-	-	-	-	-	-	-

AMPH Balance Sheet

Amphastar Pharmaceuticals, Inc. (AMPH) balance sheet — assets, liabilities & shareholders' equity

Line item	Dec'17	Dec'18	Dec'19	Dec'20	Dec'21	Dec'22	Dec'23	Dec'24	Dec'25
Total Current Assets	187.78M	220.34M	255.24M	279.68M	318.12M	378.32M	489.6M	534.07M	636.02M
Cash & Short-Term Investments	68.23M	89.17M	89.52M	105.62M	136.67M	175.76M	256.81M	221.65M	282.81M
Cash Only	65.59M	86.34M	75.55M	92.64M	126.35M	156.1M	144.3M	151.61M	170.18M
Short-Term Investments	2.63M	2.83M	13.96M	12.98M	10.32M	19.66M	112.51M	70.04M	112.64M
Accounts Receivable	36M	52.16M	45.38M	66M	78.8M	88.8M	115.47M	138.04M	143.56M
Days Sales Outstanding	54.7	64.61	51.38	68.86	65.7	64.96	65.4	68.83	72.79
Inventory	63.61M	69.32M	110.5M	96.83M	92.81M	103.58M	105.83M	153.74M	176.89M
Days Inventory Outstanding	155.42	134.82	211.79	171.15	142.31	151.16	131.72	156.7	177.46
Other Current Assets	10.19M	4.2M	9.85M	4.45M	2.56M	2.61M	11.49M	20.65M	32.75M
Total Non-Current Assets	266.89M	293.22M	331.73M	351.55M	353.41M	363.67M	1.02B	1.04B	993.28M
Property, Plant & Equipment	185.34M	210.42M	253.55M	280.71M	271.49M	264.57M	315.64M	344.63M	353.72M
Fixed Asset Turnover	1.30x	1.40x	1.27x	1.25x	1.61x	1.89x	2.04x	2.12x	2.04x
Goodwill	4.46M	3.95M	3.63M	3.94M	3.31M	3.13M	3.22M	3.05M	3.4M
Intangible Assets	40.68M	38.32M	37.52M	36.67M	35.56M	34.17M	610.08M	587.61M	562.56M
Long-Term Investments	0	0	0	0	3.98M	2.41M	15.21M	11M	0
Other Non-Current Assets	8.66M	9.92M	11.16M	5.25M	16.66M	20.86M	25.91M	25.99M	31.14M
Total Assets	454.67M▲ 0%	513.56M▲ 13.0%	586.97M▲ 14.3%	631.24M▲ 7.5%	671.53M▲ 6.4%	741.99M▲ 10.5%	1.51B▲ 103.9%	1.58B▲ 4.3%	1.63B▲ 3.3%
Asset Turnover	0.53x	0.57x	0.55x	0.55x	0.65x	0.67x	0.43x	0.46x	0.44x
Asset Growth %	6.3%	12.95%	14.29%	7.54%	6.38%	10.49%	103.9%	4.27%	3.29%
Total Current Liabilities	67.19M	106.83M	90.01M	112.2M	103.81M	94.86M	225.41M	173.76M	158.16M
Accounts Payable	16.63M	31.32M	25.06M	24.36M	22.21M	20.5M	25.44M	30.51M	32.59M
Days Payables Outstanding	40.63	60.92	48.03	43.05	34.06	29.92	31.66	31.1	32.7
Short-Term Debt	6.31M	18.23M	10.92M	12.26M	2.2M	3.05M	436K	234K	1.64M
Deferred Revenue (Current)	0	-56.09M	0	0	0	0	0	0	0
Other Current Liabilities	7.78M	0	30.12M	25.19M	23.16M	17.55M	0	0	0
Current Ratio	2.79x	2.06x	2.84x	2.49x	3.06x	3.99x	2.17x	3.07x	4.02x
Quick Ratio	1.85x	1.41x	1.61x	1.63x	2.17x	2.90x	1.70x	2.19x	2.90x
Cash Conversion Cycle	169.5	138.51	215.14	196.96	173.95	186.2	165.46	194.43	217.55
Total Non-Current Liabilities	50.14M	42.37M	69.43M	70.31M	122.2M	118.47M	648.08M	671.41M	682.34M
Long-Term Debt	40.84M	31.98M	38.89M	33.91M	74.38M	72.84M	589.58M	601.63M	608.66M
Capital Lease Obligations	0	0	16.82M	17.74M	25.1M	23.69M	29.72M	41.88M	37.77M
Deferred Tax Liabilities	2.24M	1.45M	867K	5.45M	7.07M	7.37M	6.07M	6.96M	5.93M
Other Non-Current Liabilities	7.94M	9.36M	12.86M	13.21M	15.65M	14.56M	22.72M	20.95M	29.98M
Total Liabilities	117.34M	149.2M	159.44M	182.51M	226.01M	213.33M	873.49M	845.17M	840.49M
Total Debt	47.16M	50.21M	66.63M	67.27M	104.66M	102.58M	623.64M	650.55M	656M
Net Debt	-18.44M	-36.12M	-8.93M	-25.37M	-21.69M	-53.52M	479.35M	498.94M	485.82M
Debt / Equity	0.14x	0.14x	0.16x	0.15x	0.23x	0.19x	0.98x	0.89x	0.83x
Debt / EBITDA	3.16x	6.36x	3.16x	1.86x	1.09x	0.76x	2.61x	2.48x	4.40x
Net Debt / EBITDA	-1.24x	-4.58x	-0.42x	-0.70x	-0.22x	-0.39x	2.01x	1.90x	3.26x
Interest Coverage	2.51x	-39.85x	507.12x	13.40x	96.07x	63.86x	7.31x	7.25x	5.85x
Total Equity	337.33M▲ 0%	364.36M▲ 8.0%	427.53M▲ 17.3%	448.72M▲ 5.0%	445.52M▼ 0.7%	528.66M▲ 18.7%	639.42M▲ 21.0%	732.3M▲ 14.5%	788.8M▲ 7.7%
Equity Growth %	2.45%	8.01%	17.34%	4.96%	-0.71%	18.66%	20.95%	14.53%	7.72%
Book Value per Share	6.97	7.85	8.57	9.13	8.95	10.08	12.06	14.07	16.36
Total Shareholders' Equity	337.33M	332.44M	381.37M	402.31M	445.52M	528.66M	639.42M	732.3M	788.8M
Common Stock	5K	5K	5K	5K	6K	6K	6K	6K	6K
Retained Earnings	76.23M	67.48M	116.37M	117.77M	180.34M	271.72M	409.27M	568.79M	666.88M
Treasury Stock	-50.7M	-75.48M	-97.63M	-121.81M	-150.48M	-189.52M	-247.43M	-332.71M	-408.15M
Accumulated OCI	-2.1M	-4.01M	-4.69M	-3.72M	-6.76M	-8.62M	-8.48M	-9.18M	-5.31M
Minority Interest	0	31.92M	46.16M	46.42M	0	0	0	0	0

AMPH Cash Flow Statement

Amphastar Pharmaceuticals, Inc. (AMPH) cash flow — operating, investing & free cash flow history

Line item	Dec'17	Dec'18	Dec'19	Dec'20	Dec'21	Dec'22	Dec'23	Dec'24	Dec'25
Cash from Operations	39.21M	38.19M	41.76M	57.27M	97.99M	89.18M	183.5M	213.39M	156.12M
Operating CF Margin %	16.33%	12.96%	12.96%	16.37%	22.38%	17.87%	28.48%	29.15%	21.69%
Operating CF Growth %	1.68%	-2.6%	9.35%	37.12%	71.12%	-8.99%	105.76%	16.28%	-26.84%
Net Income	4.51M	-6.66M	46.51M	1.1M	63.3M	91.39M	137.54M	159.52M	98.09M
Depreciation & Amortization	15.44M	16.52M	21.12M	25.18M	26.75M	28.74M	41.78M	57.2M	63.2M
Stock-Based Compensation	17.09M	16.68M	17.3M	20.5M	18.69M	17.86M	20.24M	24.37M	27.28M
Deferred Taxes	3.93M	-1.88M	7.55M	1.12M	4.21M	-15.75M	-13.74M	-17.87M	27.63M
Other Non-Cash Items	-2.34M	1.43M	1.04M	240K	-13.03M	-878K	21.89M	4.71M	5.89M
Working Capital Changes	582K	12.1M	-51.75M	9.13M	-1.92M	-32.18M	-24.21M	-14.55M	-65.97M
Change in Receivables	-8.1M	-16.3M	6.7M	-20.16M	-14.92M	-10.13M	-26.09M	-21.67M	-6.37M
Change in Inventory	18.65M	-5.98M	-41.1M	15.3M	1.26M	-11.75M	-1.72M	-48.8M	-21.06M
Change in Payables	6.69M	29.16M	-17.94M	14.96M	3.02M	-736K	13.24M	63.56M	-4.56M
Cash from Investing	-38.76M	-42.18M	-50.53M	-36.41M	-28.67M	-32.78M	-649.12M	-124.93M	-70.33M
Capital Expenditures	-35.1M	-46.81M	-41.55M	-33.85M	-27.46M	-24.03M	-38.17M	-41.04M	-34.88M
CapEx % of Revenue	14.61%	15.89%	12.89%	9.68%	6.27%	4.82%	5.92%	5.61%	4.85%
Acquisitions	2M	4.64M	0	0	0	421K	-506.41M	-129M	0
Investments	-	-	-	-	-	-	-	-	-
Other Investing	-3.66M	198K	-157K	-1.41M	-2.61M	-1.37M	1.39M	-4.12M	-6.61M
Cash from Financing	-7.72M	25.01M	-3.78M	-2.25M	-37.02M	-26.44M	454.09M	-80.95M	-67.42M
Debt Issued (Net)	9.27M	3.07M	-3.21M	-880K	32.1M	-1.78M	526.34M	10.17M	5.31M
Equity Issued (Net)	-30.75M	12.99M	-3.99M	-24.43M	-28.87M	-39.91M	-58.14M	-85.46M	-72.73M
Dividends Paid	0	0	0	0	0	0	0	0	0
Share Repurchases	-30.75M	-25.05M	-22.29M	-24.43M	-28.87M	-39.91M	-58.14M	-85.46M	-75.59M
Other Financing	13.76M	8.95M	3.42M	23.06M	-40.24M	15.25M	-14.11M	-5.67M	0
Net Change in Cash	-6.76M▲ 0%	20.74M▲ 406.8%	-12.65M▼ 161.0%	18.96M▲ 249.8%	32.08M▲ 69.2%	29.75M▼ 7.3%	-11.8M▼ 139.7%	7.31M▲ 162.0%	18.57M▲ 153.9%
Free Cash Flow	4.11M▲ 0%	-8.62M▼ 309.7%	207K▲ 102.4%	23.41M▲ 11209.7%	70.54M▲ 201.3%	65.15M▼ 7.6%	145.34M▲ 123.1%	172.34M▲ 18.6%	121.23M▼ 29.7%
FCF Margin %	1.71%	-2.92%	0.06%	6.69%	16.11%	13.06%	22.55%	23.55%	16.84%
FCF Growth %	-76.07%	-309.66%	102.4%	11209.66%	201.3%	-7.64%	123.09%	18.58%	-29.66%
FCF per Share	0.08	-0.19	0.00	0.48	1.42	1.24	2.74	3.31	2.51
FCF Conversion (FCF/Net Income)	8.70x	-6.66x	0.85x	40.82x	1.58x	0.98x	1.33x	1.34x	1.59x
Interest Paid	1.88M	2.38M	2.44M	2.2M	2.11M	3.02M	17.57M	26.81M	23.22M
Taxes Paid	4.88M	339K	5.72M	3.41M	8.1M	44.44M	49M	40.1M	22.71M

AMPH Key Ratios

Amphastar Pharmaceuticals, Inc. (AMPH) financial ratios — P/E, ROE, debt and 30+ core market and balance-sheet ratios

Metric	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025
Return on Equity (ROE)	3.37%	1.35%	-1.64%	12.36%	0.32%	13.89%	18.76%	23.55%	23.26%	12.9%
Return on Invested Capital (ROIC)	4.16%	-0.22%	-2%	-0.01%	1.95%	12.37%	17.94%	18.54%	13.11%	8.4%
Gross Margin	40.83%	37.8%	36.31%	40.92%	40.97%	45.63%	49.87%	54.49%	51.08%	49.46%
Net Margin	4.13%	1.88%	-1.95%	15.18%	0.4%	14.19%	18.31%	21.34%	21.79%	13.63%
Debt / Equity	0.11x	0.14x	0.14x	0.16x	0.15x	0.23x	0.19x	0.98x	0.89x	0.83x
Interest Coverage	15.60x	2.51x	-39.85x	507.12x	13.40x	96.07x	63.86x	7.31x	7.25x	5.85x
FCF Conversion	3.66x	8.70x	-6.66x	0.85x	40.82x	1.58x	0.98x	1.33x	1.34x	1.59x
Revenue Growth	1.45%	-5.87%	22.69%	9.4%	8.53%	25.13%	13.98%	29.14%	13.59%	-1.65%

AMPH SEC Filings & Documents

Amphastar Pharmaceuticals, Inc. (AMPH) SEC filings — annual & quarterly reports (10-K, 10-Q)

8-K Announcements

Material company update

Mar 16, 2026·SEC

Material company update

Mar 6, 2026·SEC

Material company update

Mar 6, 2026·SEC

10-K Annual Reports

FY 2026

Feb 26, 2026·SEC

FY 2025

Mar 3, 2025·SEC

FY 2024

Feb 29, 2024·SEC

10-Q Quarterly Reports

FY 2025

Nov 6, 2025·SEC

FY 2025

Aug 7, 2025·SEC

FY 2025

May 8, 2025·SEC

AMPH Frequently Asked Questions

Amphastar Pharmaceuticals, Inc. (AMPH) stock FAQ — growth, dividends, profitability & financials explained

Growth & Financials

Amphastar Pharmaceuticals, Inc. (AMPH) reported $719.9M in revenue for fiscal year 2025. This represents a 252% increase from $204.3M in 2012.

Amphastar Pharmaceuticals, Inc. (AMPH) saw revenue decline by 1.7% over the past year.

Yes, Amphastar Pharmaceuticals, Inc. (AMPH) is profitable, generating $98.1M in net income for fiscal year 2025 (13.6% net margin).

Dividend & Returns

Amphastar Pharmaceuticals, Inc. (AMPH) has a return on equity (ROE) of 12.9%. This is reasonable for most industries.

Amphastar Pharmaceuticals, Inc. (AMPH) generated $121.2M in free cash flow for fiscal year 2025. Positive FCF indicates the company can fund dividends, buybacks, or reinvestment.

Explore More AMPH

Amphastar Pharmaceuticals, Inc. (AMPH) financial analysis — history, returns, DCA and operating performance tools

Total Return Calculator

Historical returns with dividends reinvested

→

DCA Calculator

Dollar cost averaging vs lump sum

→

Dividend History

Yield, growth, payout safety & DRIP

→

Earnings History

EPS trends, net income & profitability

→

Price History

Long-term charts & historical price data

→

Revenue History

Sales growth patterns & revenue breakdown

→

Financial Ratios

30 years of market, efficiency and balance-sheet ratios

→

Valuation

DCF intrinsic value, peer multiples & estimates

→

Amphastar Pharmaceuticals, Inc.(AMPH)Earnings, Financials & Key Ratios

AMPH Key Insights

✓Strengths

✗Weaknesses

AMPH Price & Volume

AMPH Growth Metrics

Revenue CAGR

Profit CAGR

EPS CAGR

Return on Capital

AMPH Recent Earnings

AMPH Peer Comparison

Compare AMPH vs Peers

vs LNTH

vs MCK

Compare Top 5

AMPH Income Statement

AMPH Balance Sheet

AMPH Cash Flow Statement

AMPH Key Ratios

AMPH SEC Filings & Documents

8-K Announcements

10-K Annual Reports

10-Q Quarterly Reports

AMPH Frequently Asked Questions

Explore More AMPH

Total Return Calculator

DCA Calculator

Dividend History

Earnings History

Price History

Revenue History

Financial Ratios

Valuation